Search Results
Results found for "Strosberg AD"
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
While writing a literature review on opioid and alcohol addiction susceptibility, something shifted. drug combinations that mirror contamination patterns, and experimental designs that evolve with new adulterants She is especially interested in mu-opioid receptor signaling and how xylazine, as an alpha-2 adrenergic
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa Misinterpreting displacement curves in allosteric assays means discarding viable compounds—or worse, advancing GPCR Premium Membership Gives You an Edge The GPCR field is advancing at breakneck speed.
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
Terry Kenakin's insights on target residence time can reshape how you evaluate and advance lead compounds fentanyl slows inhalation via opioid receptors, while xylazine prolongs exhalation through alpha-2 adrenergic Competitive Edge: Stay informed on emerging public health threats and the scientific research aimed at addressing Listen now to understand how two mechanisms intersect—and why pharmacologists are critical in addressing GPCR University Course Attendee Ready to gain a competitive advantage?
- Fluorescence Polarization in GPCR Research
Adapted from: Zhang Y, Tang H, Chen W, Zhang J. Optimizing GPCR Drug Discovery with Fluorescence Polarization: Key Advantages and Future Perspectives Advancing Fluorescence Polarization Assays with Custom Fluorescent Ligands Looking ahead, fluorescence expected to expand its role in GPCR research through the development of novel fluorescent probes and advanced Contact us to drive further advancements in GPCR drug discovery!
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
, Catherine Demery’s research is about receptors and signaling pathways—how mu-opioid and alpha-2 adrenergic The combination is not merely additive; it’s synergistic, shrinking tidal volume even when breathing With street-level contamination rising faster than medicine can adapt, Catherine’s work shows why overdose But that mechanism has no impact on xylazine, which works through alpha-2 adrenergic receptors. And the illicit supply is moving faster than clinical medicine can adjust.
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
organized by both the EFMC and the ACSMEDI, in an effort to share the most novel medicinal chemistry advancements She has a lot of experience working for bigger businesses which she now shares as an advisor for startups table discussion with these excellent scientists felt like a dream come true, and Maria enjoyed giving advice
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
It is involved in several pathophysiological processes such as Parkinson’s disease, depression, addiction homogeneous conditions, using lanthanide (europium, terbium) as donors.[17] Lanthanides provide unique advantages Specific binding is shown, obtained from total binding and unspecific binding ( a ) CB1R expressing adherent measurement (specific binding measured using CP55490 at 10 μM concentration) ( b ) CB2R expressing adherent Chem. 2019 , 62 (1), 276–287. https://doi.org/10.1021/acs.jmedchem.8b00368 . (9) Adams, A.
- Radioligands vs. Fluorescent Ligands: Binding Assays
Radioligands have been used to study GPCRs for decades, but with the advances in the fluorescence field They have several advantages, such as the minimal chemical modifications in the original ligand, high Representative images of non-fixed HCTT116 colorectal tumor cells co-stained with hA2B-A3 adenosine receptor Images were taken 2 min after the addition of Celt-327 to the medium. - Fluorescent probe
- Conjugation Strategies for Probe Development
and commonly used method is the amide coupling using acid and amine .[ 1 ] This method has several advantages only do they work in aqueous medium, but also in aprotic solvents like DMF, where you will need to add Its biggest advantage is the presence of Cys residues in proteins, although sometimes S-S bridge reduction
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
This iterative process of continuous, planned improvement ensures you're always addressing the next critical
- Exclusive Access: Terry's Corner is LIVE + Your Premium Member Discount!
space to revisit core pharmacology concepts, master new ones, and sharpen your thinking to directly advance
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
Add a data scientist. Surely more hands will move the needle. And when you chain your highest-paid scientists to repetitive admin work, you’re not solving problems Ambiguous Decision Gates: Molecules advance or stall based on vibes, not criteria.
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
Alessandro admits he struggled at first with handing over parts of his projects, fearing mistakes.
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Elevate Your GPCR Science with Essential Frameworks for Precision Drug Discovery: An Insight into Advanced orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults This event is a critical opportunity to stay informed, but the real advantage lies in applying these ” - DrGPCR University Course Attendee Get a competitive advantage—Join Dr.
- Breaking the Myth of High and Low Affinity Sites
matter—and when they don’t ✅ Guidance on extracting meaningful information from binding experiments that advance
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
GPCRs Aren’t Just Surface Receptors Anymore From β2-adrenoreceptors to CCRs and dopamine receptors, multiple
- How Fast Does a Drug Work?
Kinetic measurements reveal hidden liabilities or advantages that static affinity numbers cannot. These aren’t theoretical questions—they directly impact your ability to advance the best candidates faster
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Must-read publications: A deep dive into proximity-dependent proteomics of adenylyl cyclase isoforms Bridge the gap between disciplines: Get practical advice from a computational expert on how wet-lab To succeed, you need to move beyond standard approaches and adopt the frameworks that are driving real
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
Whether working on opioid withdrawal, addiction vulnerability, or chronic pain, GPCR-related signaling
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
Breakthroughs this week: Structure-based discovery of positive allosteric modulators of the A1 adenosine insights: Structure-Based Drug Design Summit; AI-Powered GPCR Research; Lab-in-the-Loop Hit Discovery advances Terry Kenakin’s featured talk on “The Kinetics of Allostery” offers a rare live glimpse into advanced
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientist’s Mission
He’s focused on RGS proteins , pain comorbidities like addiction and depression, and pushing for more
- Understanding Orthosteric Binding: The Key to Drug Action
Key Concepts in Binding Terry unpacks several key concepts related to orthosteric binding: Langmuir Adsorption Additionally, competitive inhibitors can interfere with this binding process, leading to reduced efficacy By considering factors like the Langmuir adsorption isotherm and binding curves, researchers can better
- From GPCR Data Chaos to Decisive Action
That’s Why I Built Yamina’s Consulting Corner This is not “advising.” Unlike traditional advisors, I'm not just observing; I'm part of your team . Corner helps teams move from data chaos to decisive action ✅ This is hands-on support —not passive advising
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
Advances in biased signaling, allosterism, and endosomal signaling have opened new therapeutic frontiers
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
UConn accepted the research done in the BMS lab as part of the dissertation Sokhom met weekly with advisors path is a model of possibility for professionals in the biotech industry who still dream of earning advanced
- Pharmacology at Your Fingertips: Terry’s Corner Launches
ligands differently activate class A GPCR NMBR, with allosteric communication hubs modulating signaling, advancing
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
core models—fundamentals that fuel confidence and fluency Move beyond theory to apply selectivity, ADME , and early safety in real development contexts Advance with nuanced lessons on allostery, residence
- From Multiplex to Models: Scaling Up GPCR Discovery in the Post-Silo Era
proximity, immuno assays, pulldowns Validated antibodies + digital search platform Entire library hosted on Addgene
- Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs
Kotliar sees a future where this system is not just used for detection, but for functional screening : add
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
What emerged was a dual-tagged GPCR library (DUET constructs), now publicly available via Addgene ,






























